Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study
Krishna Mohan Vadrevu, Siddharth Reddy, Harsh Jogdand, Brunda Ganneru, Nizam Mirza, Virendra Nath Tripathy, Chandramani Singh, Vasant Khalatkar, Siddaiah Prasanth, Sanjay Rai, Raches Ella, William C. Blackwelder, Sai Prasad, Krishna M. Ella
Topics & Concepts
ReactogenicityMedicineImmunogenicityVaccinationAdverse effectInterim analysisPediatricsPandemicSerologyInternal medicineImmunologyRandomized controlled trialAntibodyCoronavirus disease 2019 (COVID-19)DiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyImmune responses and vaccinations